Zai Lab Past Earnings Performance
Past criteria checks 0/6
Zai Lab's earnings have been declining at an average annual rate of -18.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 55.4% per year.
Key information
-18.3%
Earnings growth rate
-9.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 55.4% |
Return on equity | -42.0% |
Net Margin | -125.5% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
A Risky Bet: Zai Lab's Uncertain Future
Apr 16Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop
Mar 29We're Hopeful That Zai Lab (NASDAQ:ZLAB) Will Use Its Cash Wisely
Mar 24Why Investors Shouldn't Be Surprised By Zai Lab Limited's (NASDAQ:ZLAB) Low P/S
Jan 18Here's Why We're Not Too Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Situation
Sep 22Zai Lab Limited's (NASDAQ:ZLAB) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Jun 02Is Zai Lab Limited (NASDAQ:ZLAB) Trading At A 44% Discount?
Feb 16Zai Lab (NASDAQ:ZLAB) Is In A Good Position To Deliver On Growth Plans
Jan 20We Think Zai Lab (NASDAQ:ZLAB) Can Afford To Drive Business Growth
Sep 19Zai Lab GAAP EPS of -$0.14 beats by $0.92, revenue of $48.17M beats by $1.04M
Aug 09China accepts Zai Lab's biologics license application for neuromuscular disorder drug
Jul 13Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
Jun 03As Losses Narrow, Is Zai Lab Finally Finding Its Winning Formula?
May 18Zai Lab Revenue Triples As It Struggles To Break Cycle Of Mounting Losses
Mar 08Bearish: Analysts Just Cut Their Zai Lab Limited (NASDAQ:ZLAB) Revenue and EPS estimates
Mar 06Revenue & Expenses BreakdownBeta
How Zai Lab makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 267 | -335 | 282 | 0 |
30 Sep 23 | 263 | -301 | 271 | 0 |
30 Jun 23 | 252 | -393 | 269 | 0 |
31 Mar 23 | 231 | -410 | 264 | 0 |
31 Dec 22 | 215 | -443 | 259 | 0 |
30 Sep 22 | 197 | -593 | 257 | 0 |
30 Jun 22 | 182 | -529 | 249 | 0 |
31 Mar 22 | 171 | -554 | 240 | 0 |
31 Dec 21 | 144 | -704 | 219 | 0 |
30 Sep 21 | 115 | -569 | 190 | -160 |
30 Jun 21 | 87 | -537 | 159 | -102 |
31 Mar 21 | 61 | -454 | 128 | -34 |
31 Dec 20 | 49 | -269 | 111 | 0 |
30 Sep 20 | 39 | -239 | 93 | 192 |
30 Jun 20 | 29 | -240 | 83 | 185 |
31 Mar 20 | 19 | -201 | 74 | 146 |
31 Dec 19 | 13 | -195 | 70 | 0 |
30 Sep 19 | 8 | -212 | 58 | 166 |
30 Jun 19 | 4 | -181 | 45 | 145 |
31 Mar 19 | 2 | -160 | 33 | 132 |
31 Dec 18 | 0 | -139 | 22 | 120 |
30 Sep 18 | 0 | -89 | 14 | 74 |
30 Jun 18 | 0 | -67 | 14 | 53 |
31 Mar 18 | 0 | -59 | 13 | 46 |
31 Dec 17 | 0 | -50 | 12 | 39 |
30 Sep 17 | 0 | -50 | 10 | 41 |
30 Jun 17 | 0 | -50 | 8 | 44 |
31 Mar 17 | 0 | -44 | 7 | 38 |
31 Dec 16 | 0 | -38 | 6 | 32 |
Quality Earnings: ZLAB is currently unprofitable.
Growing Profit Margin: ZLAB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZLAB is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.
Accelerating Growth: Unable to compare ZLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZLAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ZLAB has a negative Return on Equity (-42.03%), as it is currently unprofitable.